Navigation Links
Respironics, Inc. Issues Voluntary Recall of a Limited Number of Trilogy Ventilators
Date:7/17/2012

MURRYSVILLE, Pa., July 17, 2012 /PRNewswire/ -- Respironics, Inc. announced today that it is voluntarily recalling 80 Trilogy Model 100 and five Trilogy Model 202 ventilators in the United States. The recall was initiated on April 27, 2012 and is being conducted to replace a potentially defective electronic component. Respironics has received no reports from users of ventilator malfunction, injury or death related to this issue.

The Trilogy 100 ventilator provides volume and pressure support ventilation for adult and pediatric patients in both invasive and noninvasive home, institution/hospital, and portable applications. The Trilogy 202 is for hospital use and allows blending of external oxygen with volume and pressure support. The Trilogy 200 ventilator model distributed in the United States is not affected by this recall.

The defective component is in the power supply of the ventilators, and if it fails, there may be a reduction or cessation of ventilator therapy and/or the ventilator may fail to alarm and alert caregivers to this situation. Failure of a caregiver to respond to a failed device could result in harm to a ventilator dependent patient.

Respironics has notified all United States distributors, providers, sales personnel and customers that may have devices subject to this recall. Replacement units have been shipped to all affected customers. To date, all affected Trilogy 202 devices have been returned, and Respironics is working to arrange the return of the nine affected Trilogy 100 units that remain with customers. Customers with questions about this recall may contact Respironics Customer Service at 1-877-387-3311. 

Respironics has notified the U.S. Food & Drug Administration (FDA) of its decision to voluntarily recall the affected product. Any adverse reactions experienced with the use of this product should be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch. Adverse reactions and/or quality problems should also be reported to Philips Respironics at 1-800-345-6443. 


'/>"/>
SOURCE Respironics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
2. MLB All-Star Pitcher CC Sabathia Issues Fast Relief Challenge to Generate Donations for the American Red Cross
3. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
4. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
5. OncoSec Medical Issues Letter to Shareholders
6. Ameritox Announces Educational Resources to Help Physicians Navigate Complex Compliance Issues
7. BD Issues 2011 Sustainability Report
8. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
9. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
10. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... Western ... Resources and Services Administration (HRSA) grant to train predoctoral dental students in providing ... in rural and underserved areas. , The Predoctoral Pediatric Training Project (PPTP), a ...
(Date:7/20/2017)... ... , ... A July 5th article on Reuters Health News discusses ... a body contouring procedure reported experiencing a better quality of life, compared to other ... both types of procedures, notes that this report jibes with what they regularly hear ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... “Fidget”: a ... Sisk, a retired public high school music and drama teacher who was a summa ... educational career, including a “Teacher of the Year” award. After her retirement from public ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... CannaKids, a ... extracted cannabis oils, announced today that at the WORLDZ Summit, taking place in ... speaking on the therapeutic benefits of medical cannabis for both pediatric and adult patients, ...
(Date:7/18/2017)... ... 18, 2017 , ... ClinicalTrials.gov and the New Final Rule ... Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — 1:30 p.m. – 3:00 p.m. ... Clinical Trials Registration and Results Information,” is a head-scratcher. After reading and re-reading ...
Breaking Medicine News(10 mins):